Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSResearch Question:
Efficacy of frontline treatment of relapsed AML or MDS following allo-HCT.
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment
of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4
cycles of combined modality treatment. The number of cycles depends on response, toxicity,
and the remaining cell dose.
Study Reference #: ULEU18130
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Haley Misch
Phone: (585) 275-9485
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search